AstraZeneca PLC (LON:0A4J)

Market Cap	220.48B
Revenue (ttm)	43.24B
Net Income (ttm)	6.99B
Shares Out	n/a
EPS (ttm)	4.48
PE Ratio	31.53
Forward PE	18.92
Dividend	1.14 (1.20%)
Ex-Dividend Date	Aug 8, 2025

Volume	179
Average Volume	6,964
Open	95.10
Previous Close	n/a
Day's Range	95.10 - 95.10
52-Week Range	64.50 - 95.10
Beta	0.18
RSI	72.78
Earnings Date	Feb 10, 2026

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B...

• Industry: Pharmaceutical Preparations
• Founded: 1992
• Employees: 94,300
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A4J

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD